Sadatoshi Furukado - Santen Pharmaceutical Director
Director
Mr. Sadatoshi Furukado resigned from the position of Executive Vice President and Director in Santen Pharmaceutical Co., Ltd. effective June 23, 2017. He joined the Company in April 1977. His previous titles include Senior Managing Executive Officer, Senior Director of Medicine Sales, Executive Officer and Managing Executive Officer in the Company.
| Age | 62 |
| Phone | 81 6 7664 8621 |
| Web | https://www.santen.com |
Santen Pharmaceutical Management Efficiency
Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 32.93 B in total debt with debt to equity ratio (D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Santen Pharmaceutical has a current ratio of 2.43, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Santen Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Santen Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Santen Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Santen to invest in growth at high rates of return. When we think about Santen Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Erik Fyrwald | Eli Lilly and | 58 | |
| Vindi Banga | GlaxoSmithKline PLC ADR | N/A | |
| Raul Alvarez | Eli Lilly and | 65 | |
| Deryck Maughan | GlaxoSmithKline PLC ADR | 66 | |
| Christian Mulliez | Sanofi | 57 | |
| Karen Walker | Eli Lilly and | 59 | |
| Antonio Pares | Grifols SA ADR | N/A | |
| Dimitri Azar | Novartis AG | 59 | |
| Igor Landau | Sanofi | 70 | |
| SuetFern Lee | Sanofi ADR | 59 | |
| Pamela Craig | Merck Company | 64 | |
| Emmanuel Babeau | Sanofi | 51 | |
| Nazneen Rahman | AstraZeneca PLC ADR | N/A | |
| Ann Cairns | AstraZeneca PLC ADR | 57 | |
| Ian Davis | Johnson Johnson | 70 | |
| Alan Lacy | Bristol Myers Squibb | 64 | |
| Ann Cairns | AstraZeneca PLC | 57 | |
| Roy Roberts | AbbVie Inc | 69 | |
| Diane Souza | Sanofi ADR | 65 | |
| Rochelle Lazarus | Merck Company | 71 | |
| Charles Prince | Johnson Johnson | 71 | |
Management Performance
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 |
Santen Pharmaceutical Leadership Team
Elected by the shareholders, the Santen Pharmaceutical's board of directors comprises two types of representatives: Santen Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santen. The board's role is to monitor Santen Pharmaceutical's management team and ensure that shareholders' interests are well served. Santen Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santen Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Satoshi Suzuki, Executive Officer, Chief Director of Planning | ||
| Kanoko Ohishi, Independent Director | ||
| Nikolas Tripodis, Chief Officer | ||
| Noriaki Yamamoto, CIO, Head of Information Systems Division and Corporate Officer | ||
| Akira Kurokawa, CEO and President Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee | ||
| Hidetaka Mizutani, Manager of Finance & Accounting Group | ||
| Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR | ||
| Nobuko Kato, Chief Officer | ||
| Sadatoshi Furukado, Senior Managing Executive Officer, Director of Medical Business, Director | ||
| Ken Araki, Executive Officer, Senior Director of Global Business Development | ||
| Mika Masunari, G Officer | ||
| Masamichi Sato, Head of CSR and General Affairs Division and Sr. Corporate Officer of Corporate Devel. | ||
| Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer | ||
| Kaori Itagaki, Gen Group | ||
| Akihiro Tsujimura, Executive Officer, Director of Asia Business | ||
| Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit | ||
| Shinichi Teramachi, Head Officer | ||
| Frank Binder, Executive Officer, Chief Director of Supply Chain | ||
| Ippei Kurihara, Japan Department | ||
| Yutaro Shintaku, Independent Director | ||
| Akihiro Okumura, Independent Director | ||
| Yutaro Shinta, Independent Director | ||
| Jyrki Liljeroos, Executive Officer and Presidentident of Subsidiary | ||
| Shiro Hatagami, Manager of Finance & Accounting Group | ||
| Keizo Nakada, Executive Officer, Chief Director of Product Supply | ||
| Ko Takahashi, Executive Officer | ||
| Akio Kimura, Executive Officer, Chief Director of Reliability Guarantee | ||
| Miki Fujima, Executive Officer, Chief Director of Human Resources | ||
| Naveed Shams, Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary | ||
| Atsutoshi Ohta, Executive Officer, Chief Director of Production & Logistics | ||
| Hiroyuki Yamazaki, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit | ||
| Takahiro Morita, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit | ||
| Ye Liu, Executive Officer, General Manager of Subsidiary | ||
| Takayuki Katayama, Independent Director | ||
| Luis Iglesias, Executive Officer | ||
| Shigeo Taniuchi, Executive Officer and Presidentident of Subsidiary | ||
| Kunihito Minakawa, Independent Director | ||
| Minori Hara, Chief Officer |
Santen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santen Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 388.22 M | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | 14.22 X | |||
| Price To Book | 1.39 X | |||
| Price To Sales | 0.01 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Santen Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Santen Pharmaceutical's short interest history, or implied volatility extrapolated from Santen Pharmaceutical options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Santen Pharmaceutical information on this page should be used as a complementary analysis to other Santen Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |